An open-label, multicenter, multiarm, phase 1b study (NCT02715531) looked at the efficacy and safety of combining atezolizumab (anti-PD-L1 mAb) and bevacizumab (anti-VEGF mAb) in patients with unresectable HCC who had not previously received systemic therapy. The gene discussed is CD274; the disease is hepatocellular carcinoma.